2021 Q4 Form 10-Q Financial Statement

#000135657621000095 Filed on November 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $159.1M $148.5M $155.1M
YoY Change 10.76% -4.3% 51.88%
Cost Of Revenue $16.99M $18.09M $21.39M
YoY Change -8.14% -15.44% 343.83%
Gross Profit $142.1M $130.4M $133.7M
YoY Change 13.64% -2.52% 37.43%
Gross Profit Margin 89.32% 87.82% 86.21%
Selling, General & Admin $79.44M $72.03M $54.46M
YoY Change 41.34% 32.27% 38.42%
% of Gross Profit 55.92% 55.25% 40.72%
Research & Development $21.08M $19.65M $16.84M
YoY Change 17.75% 16.72% -0.61%
% of Gross Profit 14.84% 15.07% 12.59%
Depreciation & Amortization $12.71M $6.675M $7.600M
YoY Change 131.04% -12.17% 375.0%
% of Gross Profit 8.95% 5.12% 5.68%
Operating Expenses $113.7M $91.69M $71.30M
YoY Change 38.61% 28.59% 26.67%
Operating Profit $28.40M $32.60M $56.14M
YoY Change -33.96% -41.92% 41.31%
Interest Expense -$3.216M $5.925M $6.088M
YoY Change -559.43% -2.68% 7.52%
% of Operating Profit -11.32% 18.17% 10.84%
Other Income/Expense, Net -$831.0K -$3.644M -$3.429M
YoY Change -79.23% 6.27% 2366.91%
Pretax Income $2.051M $28.96M $52.71M
YoY Change -94.83% -45.06% 33.14%
Income Tax -$391.0K $7.398M $12.71M
% Of Pretax Income -19.06% 25.55% 24.12%
Net Earnings $2.442M $21.56M $40.00M
YoY Change -92.07% -46.09% 38.59%
Net Earnings / Revenue 1.54% 14.52% 25.78%
Basic Earnings Per Share $0.41 $0.76
Diluted Earnings Per Share $44.79K $0.40 $0.74
COMMON SHARES
Basic Shares Outstanding 53.18M shares 53.19M shares 52.66M shares
Diluted Shares Outstanding 54.33M shares 53.76M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $339.7M $443.9M $352.0M
YoY Change -19.6% 26.09% 18.64%
Cash & Equivalents $203.4M $215.3M $204.3M
Short-Term Investments $136.2M $228.6M $147.7M
Other Short-Term Assets $27.02M $30.69M $24.50M
YoY Change 44.49% 25.27% 34.62%
Inventory $85.96M $60.16M $42.47M
Prepaid Expenses
Receivables $148.9M $133.7M $133.1M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $601.6M $668.4M $552.0M
YoY Change -4.57% 21.08% 29.25%
LONG-TERM ASSETS
Property, Plant & Equipment $16.96M $46.58M $17.40M
YoY Change -55.17% 167.77% 74.35%
Goodwill $117.5M $77.96M $89.14M
YoY Change 50.83% -12.54%
Intangibles $784.7M $346.6M $402.3M
YoY Change 115.37% -13.83% 1441.19%
Long-Term Investments $119.2M $405.5M $388.2M
YoY Change -65.99% 4.45% -34.91%
Other Assets $49.23M $40.13M $18.32M
YoY Change 13.83% 119.02% 3092.33%
Total Long-Term Assets $1.088B $886.7M $958.0M
YoY Change 24.48% -7.45% 40.92%
TOTAL ASSETS
Total Short-Term Assets $601.6M $668.4M $552.0M
Total Long-Term Assets $1.088B $886.7M $958.0M
Total Assets $1.689B $1.555B $1.510B
YoY Change 12.3% 2.98% 36.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.331M $9.125M $11.19M
YoY Change 51.8% -18.48% 262.23%
Accrued Expenses $117.7M $72.29M $197.0M
YoY Change 49.09% -63.31% 41.83%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $3.600M
YoY Change -100.0%
Total Short-Term Liabilities $315.4M $234.7M $299.6M
YoY Change 28.67% -21.66% 100.11%
LONG-TERM LIABILITIES
Long-Term Debt $379.3M $374.8M $376.8M
YoY Change 4.82% -0.53% 10.43%
Other Long-Term Liabilities $16.38M $18.19M $9.304M
YoY Change -61.72% 95.46% -17.01%
Total Long-Term Liabilities $395.6M $18.19M $9.304M
YoY Change 824.57% 95.46% -17.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $315.4M $234.7M $299.6M
Total Long-Term Liabilities $395.6M $18.19M $9.304M
Total Liabilities $873.3M $744.6M $801.1M
YoY Change 15.02% -7.06% 45.75%
SHAREHOLDERS EQUITY
Retained Earnings $379.9M $377.5M $295.7M
YoY Change 16.36% 27.64% 77.7%
Common Stock $53.00K $53.00K $53.00K
YoY Change 0.0% 0.0% 1.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $815.9M $810.5M $708.9M
YoY Change
Total Liabilities & Shareholders Equity $1.689B $1.555B $1.510B
YoY Change 12.3% 2.98% 36.42%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income $2.442M $21.56M $40.00M
YoY Change -92.07% -46.09% 38.59%
Depreciation, Depletion And Amortization $12.71M $6.675M $7.600M
YoY Change 131.04% -12.17% 375.0%
Cash From Operating Activities $48.76M -$4.110M $5.600M
YoY Change 52.86% -173.39% -85.11%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K -$497.0K -$100.0K
YoY Change -80.0% 397.0% -80.0%
Acquisitions
YoY Change
Other Investing Activities $76.17M -$5.207M -$11.10M
YoY Change 53.88% -53.09% 40.51%
Cash From Investing Activities $76.13M -$5.704M -$11.30M
YoY Change 54.42% -49.52% 34.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -136.7M 1.324M -1.000M
YoY Change -4510.97% -232.4% -433.33%
NET CHANGE
Cash From Operating Activities 48.76M -4.110M 5.600M
Cash From Investing Activities 76.13M -5.704M -11.30M
Cash From Financing Activities -136.7M 1.324M -1.000M
Net Change In Cash -11.85M -8.490M -6.700M
YoY Change -114.05% 26.72% -122.71%
FREE CASH FLOW
Cash From Operating Activities $48.76M -$4.110M $5.600M
Capital Expenditures -$40.00K -$497.0K -$100.0K
Free Cash Flow $48.80M -$3.613M $5.700M
YoY Change 52.03% -163.39% -85.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001356576
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2020Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q3 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2020Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2021Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrent
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrent
CY2020Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021Q3 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2020Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent
CY2021Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent
CY2021Q3 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2020Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35518
dei Entity Registrant Name
EntityRegistrantName
SUPERNUS PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-2590184
dei Entity Address Address Line1
EntityAddressAddressLine1
9715 Key West Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
Rockville
dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20850
dei City Area Code
CityAreaCode
301
dei Local Phone Number
LocalPhoneNumber
838-2500
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
53180768 shares
dei Trading Symbol
TradingSymbol
SUPN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
215281000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
288640000 USD
CY2021Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
228571000 USD
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
133893000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
133676000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
140877000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
60155000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
48325000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
30692000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18682000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
668375000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
630417000 USD
CY2021Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
405479000 USD
CY2020Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
350359000 USD
CY2021Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
16471000 USD
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
37824000 USD
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
346619000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
364342000 USD
CY2021Q3 us-gaap Goodwill
Goodwill
77963000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
77911000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
40133000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
43249000 USD
CY2021Q3 us-gaap Assets
Assets
1555040000 USD
CY2020Q4 us-gaap Assets
Assets
1504102000 USD
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
72286000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
78934000 USD
CY2021Q3 supn Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
132048000 USD
CY2020Q4 supn Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
126192000 USD
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
23570000 USD
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
30900000 USD
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6807000 USD
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9082000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
234711000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
245108000 USD
CY2021Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
374788000 USD
CY2020Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
361751000 USD
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
45480000 USD
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
45800000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
37261000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28579000 USD
CY2021Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
34146000 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
35215000 USD
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
18186000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
42791000 USD
CY2021Q3 us-gaap Liabilities
Liabilities
744572000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
759244000 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53180643 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53180643 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52868482 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52868482 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
53000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
53000 USD
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
428726000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
409332000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4209000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
8975000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
377480000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
326498000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
810468000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
744858000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1555040000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1504102000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
148464000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
155135000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
420725000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
376840000 USD
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
18085000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
21388000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
58067000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
33926000 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19654000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16839000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69389000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58023000 USD
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
72032000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
54460000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
203024000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
144177000 USD
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6009000 USD
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6108000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17964000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9814000 USD
CY2021Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
80000 USD
CY2020Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
200000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-7650000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
200000 USD
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
115860000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
98995000 USD
us-gaap Costs And Expenses
CostsAndExpenses
340794000 USD
us-gaap Costs And Expenses
CostsAndExpenses
246140000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
32604000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
56140000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
79931000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
130700000 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
5925000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
6088000 USD
us-gaap Interest Expense
InterestExpense
17489000 USD
us-gaap Interest Expense
InterestExpense
17658000 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2281000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2659000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8682000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15913000 USD
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3644000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3429000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8807000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1745000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
28960000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
52711000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
71124000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
128955000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7398000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12714000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20142000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
32773000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
21562000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
39997000 USD
us-gaap Net Income Loss
NetIncomeLoss
50982000 USD
us-gaap Net Income Loss
NetIncomeLoss
96182000 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.41
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.76
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.83
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.40
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.94
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.79
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53187764 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52658850 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53053441 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52583891 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54334794 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53762642 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54301461 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53663273 shares
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
21562000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
39997000 USD
us-gaap Net Income Loss
NetIncomeLoss
50982000 USD
us-gaap Net Income Loss
NetIncomeLoss
96182000 USD
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1224000 USD
CY2020Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1659000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-4766000 USD
CY2021Q3 supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
2400000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
2283000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1224000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1659000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-4766000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2283000 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
20338000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
38338000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
46216000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
98465000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
744858000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4371000 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2247000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
5694000 USD
CY2021Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-2726000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
754444000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5476000 USD
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2749000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
23726000 USD
CY2021Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-816000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
785579000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4027000 USD
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
524000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
21562000 USD
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1224000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
810468000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
595428000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3988000 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
32000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
21518000 USD
CY2020Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-7583000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
613383000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4962000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1437000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
34667000 USD
CY2020Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
11525000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
665974000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4490000 USD
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
77000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
39997000 USD
CY2020Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1659000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
708879000 USD
us-gaap Net Income Loss
NetIncomeLoss
50982000 USD
us-gaap Net Income Loss
NetIncomeLoss
96182000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19888000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12621000 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
15000000 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
13037000 USD
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
221000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
12351000 USD
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
3636000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
845000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
3217000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
7650000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-200000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
22000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-794000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
13874000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
13440000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-479000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-280000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-7352000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
26840000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
9331000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5437000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
13351000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
11734000 USD
supn Increase Decrease In Accrued Product Returns And Rebates
IncreaseDecreaseInAccruedProductReturnsAndRebates
5856000 USD
supn Increase Decrease In Accrued Product Returns And Rebates
IncreaseDecreaseInAccruedProductReturnsAndRebates
21166000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-15726000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
856000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
78364000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
106466000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
307634000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
87890000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
152546000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
319421000 USD
supn Payments To Acquire Property Plant And Equipment And Deferred Legal Fees
PaymentsToAcquirePropertyPlantAndEquipmentAndDeferredLegalFees
2005000 USD
supn Payments To Acquire Property Plant And Equipment And Deferred Legal Fees
PaymentsToAcquirePropertyPlantAndEquipmentAndDeferredLegalFees
3375000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
950000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
297200000 USD
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
0 USD
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
15000000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-158043000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-84044000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5520000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1546000 USD
supn Proceeds From Governmental Loans And Grants
ProceedsFromGovernmentalLoansAndGrants
800000 USD
supn Proceeds From Governmental Loans And Grants
ProceedsFromGovernmentalLoansAndGrants
0 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1056000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6320000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
490000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-73359000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
22912000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
288640000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
181381000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
215281000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
204293000 USD
us-gaap Interest Paid Net
InterestPaidNet
1887000 USD
us-gaap Interest Paid Net
InterestPaidNet
2516000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
25111000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
42284000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
155135000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
420725000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
7613000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
5152000 USD
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
0 USD
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
115900000 USD
supn Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability
4120000 USD
supn Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability
25225000 USD
supn Non Cash Capitalized Cost Of Intangible Assets
NonCashCapitalizedCostOfIntangibleAssets
186000 USD
supn Non Cash Capitalized Cost Of Intangible Assets
NonCashCapitalizedCostOfIntangibleAssets
352000 USD
us-gaap Nature Of Operations
NatureOfOperations
Business Organization<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, and chronic sialorrhea. The Company is also developing a broad range of novel CNS product candidates including new potential treatments for ADHD, hypomobility in PD, epilepsy, depression, and rare CNS disorders.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Products</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trokendi XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (topiramate) is the first once-daily extended release topiramate product indicated for the treatment of epilepsy in the United States (U.S.) market. It is also indicated for the prophylaxis of migraine headache. </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Oxtellar XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (oxcarbazepine) is indicated as therapy for partial onset seizures in adults and children 6 years to 17 years of age and is the first once-daily extended-release oxcarbazepine product indicated for the treatment of epilepsy in the U.S.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Qelbree</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (viloxazine extended-release capsules) is a novel non-stimulant product indicated for the treatment of ADHD in pediatric patients 6 to 17 years of age. </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">APOKYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility or "off" episodes ("end-of-dose wearing off" and unpredictable "on-off" episodes) in patients with advanced PD. </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">MYOBLOC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rimabotulinumtoxinB) is a product indicated for the treatment of cervical dystonia and sialorrhea in adults, and it is the only Type B toxin available on the market.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">XADAGO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (safinamide) is a once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Candidates</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Qelbree (viloxazine, extended-release capsules; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SPN-812) is a novel non-stimulant product candidate for the treatment of ADHD in adult patients. The U.S. Food and Drug Administration (FDA) acknowledged it has received the supplemental new drug application (sNDA) for Qelbree for the treatment of ADHD in adult patients. The sNDA has a user fee goal date (PDUFA date) of April 29, 2022.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SPN-830 (Apomorphine Infusion Pump) is a late-stage drug/device combination product candidate for the continuous prevention of "off" episodes in PD.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SPN-817 is a novel product candidate for the treatment of severe epilepsy.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SPN-820 is a first-in-class product candidate for treatment resistant depression (TRD). It is an orally active small molecule that directly activates brain mechanistic target of rapamycin complex 1 (mTORC1).</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2021, the Company entered into an Agreement and Plan of Merger by and among the Company, Adamas Pharmaceuticals, Inc. and Supernus Reef, Inc., a Delaware corporation and a wholly owned subsidiary of the Company. Refer to Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the U.S. Food and Drug Administration (FDA) approved Qelbree (SPN-812) for the treatment of ADHD in pediatric patients 6 to 17 years of age. In May 2021, the Company launched Qelbree in the U.S. On September 2, 2021, the FDA acknowledged receiving the supplemental new drug application (sNDA) for SPN-812 for adult patients with ADHD and assigned a user fee goal date (PDUFA date) of April 29, 2022. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 28, 2020, the Company entered into a Sale and Purchase Agreement with US WorldMeds Partners, LLC to acquire the CNS portfolio of USWM Enterprises, LLC (USWM Enterprises) (USWM Acquisition). With the acquisition, completed on June 9, 2020, the Company added three established commercial products, APOKYN, XADAGO, and MYOBLOC, and a product candidate in late-stage development, SPN-830, to its portfolio. Refer to Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">USWM Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion on the USWM Acquisition. In the second quarter of 2021 and within one year from the Closing Date, the Company finalized its accounting for the business combination, including the purchase price allocation. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2020, the Company entered into a Development and Option Agreement (Development Agreement) with Navitor Pharmaceuticals, Inc. (Navitor Inc.) and also acquired an ownership position in Navitor Inc. Under the terms of the Development Agreement, the Company and Navitor Inc. will jointly conduct a Phase II clinical program for NV-5138 (SPN-820) in TRD. In March 2021, Navitor Inc. underwent a legal restructuring whereby Navitor Inc. became a wholly owned subsidiary of a newly formed limited liability company, Navitor Pharmaceuticals, LLC (Navitor LLC). Refer to Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion on the Development Agreement and equity investment.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Impact</span></div>While the impact of the ongoing COVID-19 pandemic did not have a material adverse effect on the Company's financial position or results of operations for the three and nine months ended September 30, 2021. The Company continues to closely monitor the events and circumstances surrounding the COVID-19 pandemic and its impact on all aspects of our business operations. Since the situation surrounding the COVID-19 pandemic remains fluid and the duration uncertain, the long-term nature and extent of the impacts of the pandemic on the Company's business operations and financial position cannot be reasonably estimated at this time.
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts presented as separate noncash line items in the condensed consolidated statements of cash flows have been reclassified to conform to the current year condensed financial statement presentation. These reclassifications had no effect on operating cash flows or on our other condensed consolidated financial statements for the three and nine months ended September 30, 2021 and 2020.</span></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition and results of operations is highly uncertain and subject to change. As a result, certain of our estimates and assumptions, including the provision for sales deductions, the creditworthiness of customers entering into revenue arrangements, and the fair values of our financial instruments, require increased judgment and carry a higher degree of variability and volatility that could result in material changes to our estimates in future periods.</span></div>
CY2021Q3 us-gaap Advertising Expense
AdvertisingExpense
22600000 USD
us-gaap Advertising Expense
AdvertisingExpense
59700000 USD
CY2020Q3 us-gaap Advertising Expense
AdvertisingExpense
15400000 USD
us-gaap Advertising Expense
AdvertisingExpense
37900000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
376840000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
376840000 USD
supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
6800000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
148464000 USD
CY2020Q3 supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
2400000 USD
supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
6300000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
628461000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
472306000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5878000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
11987000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
289000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
41000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
634050000 USD
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.9063
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
484252000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
228571000 USD
CY2021Q3 supn Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
220770000 USD
CY2021Q3 supn Available For Sale Securities Debt Maturities Two Years Through Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesTwoYearsThroughThreeYearsFairValue
184709000 USD
CY2021Q3 supn Available For Sale Securities Debt Maturities Three Years Through Four Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesThreeYearsThroughFourYearsFairValue
0 USD
CY2021Q3 supn Available For Sale Securities Debt Maturities Thereafter Fair Value
AvailableForSaleSecuritiesDebtMaturitiesThereafterFairValue
0 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
634050000 USD
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0 USD
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
100000 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-7700000 USD
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
76700000 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-7650000 USD
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
69050000 USD
CY2020Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
115700000 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
40900000 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
1900000 USD
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
76700000 USD
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
69050000 USD
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
76700000 USD
CY2021Q3 us-gaap Goodwill
Goodwill
77963000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
77911000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
398820000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
398579000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
52201000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
34237000 USD
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
346619000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
364342000 USD
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6000000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
18000000 USD
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6100000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9800000 USD
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52658850 shares
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4027000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4490000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13874000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13440000 USD
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53187764 shares
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.9063
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
21562000 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
39997000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
50982000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
96182000 USD
CY2019Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P10Y
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53053441 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52583891 shares
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1147030 shares
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1103792 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1248020 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1079382 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54334794 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53762642 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54301461 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53663273 shares
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.41
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.76
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.83
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.40
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.94
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.79
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
30108000 USD
CY2021Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
0 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7398000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12714000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20142000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
32773000 USD
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.255
CY2020Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.241
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.283
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.254
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20231000 USD
CY2020Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
20874000 USD
CY2021Q3 supn Lease Right Of Use Asset
LeaseRightOfUseAsset
30108000 USD
CY2020Q4 supn Lease Right Of Use Asset
LeaseRightOfUseAsset
41105000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5904000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3760000 USD
CY2021Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0 USD
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
3761000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
37261000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28579000 USD
CY2021Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
0 USD
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
20235000 USD
CY2021Q3 supn Lease Liability
LeaseLiability
43165000 USD
CY2020Q4 supn Lease Liability
LeaseLiability
56335000 USD
CY2021Q3 supn Allowance For Expected Sales Deductions
AllowanceForExpectedSalesDeductions
11200000 USD
CY2020Q4 supn Allowance For Expected Sales Deductions
AllowanceForExpectedSalesDeductions
11400000 USD
CY2021Q3 us-gaap Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
9710000 USD
CY2020Q4 us-gaap Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
22208000 USD
CY2021Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
37910000 USD
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
8985000 USD
CY2021Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
12535000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
17132000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
60155000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
48325000 USD
CY2021Q3 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
0 USD
CY2020Q4 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
22747000 USD
CY2021Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
27575000 USD
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
54864000 USD
CY2021Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
11104000 USD
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
17040000 USD
CY2021Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
16471000 USD
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
37824000 USD
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1900000 USD
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
700000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1800000 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9125000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6147000 USD
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13426000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
16008000 USD
CY2021Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
12781000 USD
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
13890000 USD
CY2021Q3 supn Accrued Product Costs Current
AccruedProductCostsCurrent
8408000 USD
CY2020Q4 supn Accrued Product Costs Current
AccruedProductCostsCurrent
9587000 USD
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
7453000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
7730000 USD
CY2021Q3 supn Accrued Clinical Trial And Clinical Supply Costs Current
AccruedClinicalTrialAndClinicalSupplyCostsCurrent
6774000 USD
CY2020Q4 supn Accrued Clinical Trial And Clinical Supply Costs Current
AccruedClinicalTrialAndClinicalSupplyCostsCurrent
12842000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5904000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3760000 USD
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8415000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8970000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
72286000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
78934000 USD
CY2021Q3 supn Accrued Rebates
AccruedRebates
98636000 USD
CY2020Q4 supn Accrued Rebates
AccruedRebates
96589000 USD
CY2021Q3 supn Accrued Product Returns
AccruedProductReturns
33412000 USD
CY2020Q4 supn Accrued Product Returns
AccruedProductReturns
29603000 USD
CY2021Q3 supn Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
132048000 USD
CY2020Q4 supn Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
126192000 USD
CY2021Q3 supn Non Recourse Liability Noncurrent
NonRecourseLiabilityNoncurrent
8139000 USD
CY2020Q4 supn Non Recourse Liability Noncurrent
NonRecourseLiabilityNoncurrent
13410000 USD
CY2021Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
0 USD
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
20235000 USD
CY2021Q3 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
10047000 USD
CY2020Q4 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
9146000 USD
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
18186000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
42791000 USD
CY2021Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
5033000 USD
CY2020Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
4945000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
14593000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
14430000 USD
CY2021Q3 us-gaap Interest Expense Other
InterestExpenseOther
892000 USD
CY2020Q3 us-gaap Interest Expense Other
InterestExpenseOther
1143000 USD
us-gaap Interest Expense Other
InterestExpenseOther
2896000 USD
us-gaap Interest Expense Other
InterestExpenseOther
3228000 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
5925000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
6088000 USD
us-gaap Interest Expense
InterestExpense
17489000 USD
us-gaap Interest Expense
InterestExpense
17658000 USD
CY2021Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
4400000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
13000000 USD
CY2020Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
4200000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
12400000 USD
CY2014Q3 supn Non Recourse Debt Sale Of Future Royalties Noncurrent
NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent
30000000 USD

Files In Submission

Name View Source Status
0001356576-21-000095-index-headers.html Edgar Link pending
0001356576-21-000095-index.html Edgar Link pending
0001356576-21-000095.txt Edgar Link pending
0001356576-21-000095-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
supn-20210930.htm Edgar Link pending
supn-20210930.xsd Edgar Link pending
supn-20210930x10qxex311.htm Edgar Link pending
supn-20210930x10qxex312.htm Edgar Link pending
supn-20210930x10qxex321.htm Edgar Link pending
supn-20210930x10qxex322.htm Edgar Link pending
supn-20210930_cal.xml Edgar Link unprocessable
supn-20210930_def.xml Edgar Link unprocessable
supn-20210930_htm.xml Edgar Link completed
supn-20210930_lab.xml Edgar Link unprocessable
supn-20210930_pre.xml Edgar Link unprocessable
supn-2021930x10qxex101.htm Edgar Link pending